# Performance of Contrast-Enhanced Spectral Mammography to Assess Neoadjuvant Chemotherapy Response (CEDM)

> **NCT04625517** · PHASE4 · TERMINATED · sponsor: **University of Texas Southwestern Medical Center** · enrollment: 6 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **PROCEDURE:** Digital Mammography
- **DRUG:** Low Osmolar Contrast Material, 300-399 Mg/Ml Iodine Concentration, Per Ml

## Key facts

- **NCT ID:** NCT04625517
- **Lead sponsor:** University of Texas Southwestern Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-01-22
- **Primary completion:** 2022-06-15
- **Final completion:** 2022-06-15
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** Low enrollment
- **Last updated:** 2023-10-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04625517

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04625517, "Performance of Contrast-Enhanced Spectral Mammography to Assess Neoadjuvant Chemotherapy Response (CEDM)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04625517. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*